Associate Professor of Medicine, University Tex Houston

Oncology

Doctor Donna M. Weber, MD works in the field of Oncology. She over the years received 1 awards: "Top Doctors:SE Texas". Donna Weber is a published doctor. She has 36 publications published. The most current publication "Crystal-storing histiocytosis: a clinicopathological study of 13 cases."

Publications

---

• Crystal-storing histiocytosis: a clinicopathological study of 13 cases.
• Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia.
• High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.
• A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma Cell survival and drug resistance.
• Primary cutaneous plasmacytoma.
• Value of novel agents and intensive therapy for patients with multiple myeloma.
• Evidence of a role for CD44 and Cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
• Durable responses with autologous hematopoietic SCT in patients with POEMS Syndrome.
• Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implic...
• PSGL-1/Selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.
• Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma.
• Curability of multiple myeloma.
• Case 181: Synovitis Acne Pustulosis Hyperostosis Osteitis (SAPHO) Syndrome.
• Case 181.
• Predictors of prolonged survival after allogeneic hematopoietic stem Cell transplantation for multiple myeloma.
• Multiple myeloma.
• Feasibility of autologous hematopoietic stem Cell transplant in patients aged ≥70 years with multiple myeloma.
• Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy.
• Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamet...
• Effect of long-term storage in TRIzol on microarray-based gene expression profiling.
• The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
• Novel agents for relapsed and/or refractory multiple myeloma.
• Autologous hematopoietic stem Cell transplantation may reverse renal failure in patients with multiple myeloma.
• Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exp...
• Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
• Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
• Nuclear BCL-10 expression is common in lymphoplasmacytic Lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation.
• Scleromyxedema: role of high-dose melphalan with autologous stem Cell transplantation.
• Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
• Solitary bone and extramedullary plasmacytoma.
• Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research Foundation.
• 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's Macroglobulinemia.
• Newly diagnosed multiple myeloma.
• Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
• Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.

Schools

---

• Southern Il Univ Sch Of Med

• Siu

• MD Anderson Canc Center

Procedures Preformed

---

• Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
• HPC Transplantation (Stem Cell Transplant)
• Plasmapheresis
• Thoracentesis

Conditions Treated

---

• Acute Leukemia
• Anemia
• Antiphospholipid Syndrome (APS)
• Aortic Embolism and Thrombosis
• View All

Doctors Specialties

---

• Hematology
• Medical Oncology
• Oncology

Accepted Insurances

---

Awards

---

• Top Doctors:SE Texas

Education

---

• University of Texas Health Science Center
• Southern Illinois University

Hospital

---

• University of Texas M.D. Anderson Cancer Center

Drug Facts

---

NPI NUMBER		1508925082
NPPES Provider LastName		WEBER
NPPES Provider FirstName		DONNA
NPPES Provider ZIPCode		770304009
NPPES Provider State		TX
Specialty Description		Medical Oncology
Total Claim Count		1221.0
Distinct Opioid Count		2.0
Opioid Claim Count		82.0
Percent Opioid Claims		6.72

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1508925082
Last Name Of The Provider	WEBER
First Name Of The Provider	DONNA
View All

Similar Doctors

---

	Dr. Charles Osborne, MD This Doctor is OpenDoctor Recommended.
	Dr. Kathy Sam, MD This Doctor is OpenDoctor Recommended.
	Dr. Wenli Liu, MD This Doctor is OpenDoctor Recommended.
	Dr. Sumit K. Subudhi, MD This Doctor is OpenDoctor Recommended.
	Dr. Joel W. Abramowitz, MD This Doctor is OpenDoctor Recommended.
	Dr. Michelle A. Fanale, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Renata Ferrarotto, MD This Doctor is OpenDoctor Recommended.
	Dr. Ana-Maria Gonzalez-Angulo, MD This Doctor is OpenDoctor Recommended.
	Dr. Jaffer A. Ajani, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Wei Lin, MD
	Dr. Philip A. Salem, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog